Study of Lademirsen (SAR339375) in Patients With Alport Syndrome
Clinical trial NCT02855268 · TERMINATED
Trial details
- NCT number
- NCT02855268
- Sponsor
- Genzyme, a Sanofi Company
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-11-02
- Primary completion
- 2022-09-22
- Enrollment
- 43
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.